NasdaqCM - Nasdaq Real Time Price USD

Salarius Pharmaceuticals, Inc. (SLRX)

Compare
1.3863 -0.0237 (-1.68%)
At close: December 16 at 4:00:00 PM EST
1.3700 -0.02 (-1.18%)
After hours: December 16 at 6:16:18 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
--
--
5,233.3010
Operating Expense
5,216.3040
12,894.9440
22,975.2310
12,812.9310
12,844.1060
Operating Income
-5,216.3040
-12,894.9440
-22,975.2310
-12,812.9310
-7,610.8050
Net Non Operating Interest Income Expense
222.6640
352.2510
218.7300
--
-3.0470
Other Income Expense
--
--
-8,851.4550
44.6930
258.5510
Pretax Income
-4,993.6400
-12,542.6930
-31,607.9560
-12,768.2380
-7,352.2540
Net Income Common Stockholders
-4,993.6400
-12,542.6930
-31,607.9560
-12,768.2380
-7,748.6610
Diluted NI Available to Com Stockholders
-4,993.6400
-12,542.6930
-31,607.9560
-12,768.2380
-7,748.6610
Basic EPS
-5.14
-30.72
-119.04
-62.00
-100.00
Diluted EPS
-5.14
-30.72
-119.04
-62.00
-100.00
Basic Average Shares
724.3540
408.0770
265.5630
206.8290
77.8930
Diluted Average Shares
724.3540
408.0770
265.5630
206.8290
77.8930
Total Operating Income as Reported
--
--
-31,841.1400
-12,812.9310
-7,786.3450
Total Expenses
5,216.3040
12,894.9440
22,975.2310
12,812.9310
12,844.1060
Net Income from Continuing & Discontinued Operation
-4,993.6400
-12,542.6930
-31,607.9560
-12,768.2380
-7,352.2540
Normalized Income
-4,993.6400
-12,542.6930
-22,756.5010
-12,812.9310
-7,610.8050
Interest Income
222.6640
352.2510
218.7300
--
--
Net Interest Income
222.6640
352.2510
218.7300
--
-3.0470
EBIT
-5,216.3040
-12,894.9440
-22,975.2310
-12,812.9310
-7,610.8050
EBITDA
-5,211.8810
-12,884.8930
-22,968.5540
-12,793.7480
-7,592.7470
Reconciled Depreciation
4.4230
10.0510
6.6770
19.1830
18.0580
Net Income from Continuing Operation Net Minority Interest
-4,993.6400
-12,542.6930
-31,607.9560
-12,768.2380
-7,352.2540
Total Unusual Items Excluding Goodwill
--
--
-8,851.4550
44.6930
258.5510
Total Unusual Items
--
--
-8,851.4550
44.6930
258.5510
Normalized EBITDA
-5,211.8810
-12,884.8930
-14,117.0990
-12,838.4410
-7,851.2980
12/31/2020 - 1/29/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ARTL Artelo Biosciences, Inc.
1.0600
-4.50%
 
XRTX XORTX Therapeutics Inc.
1.2100
-1.63%
 
QLGN Qualigen Therapeutics, Inc.
4.3900
+13.44%
 
NBY NovaBay Pharmaceuticals, Inc.
0.5675
-1.29%
 
DRMA Dermata Therapeutics, Inc.
1.0700
-1.83%
 
QNRX Quoin Pharmaceuticals, Ltd.
0.6375
-3.70%
 
AZTR Azitra, Inc.
0.4388
-0.84%
 
CYTO Altamira Therapeutics Ltd.
0.4190
-4.77%
 
SILO Silo Pharma, Inc.
0.8801
+5.39%
 
GRTX Galera Therapeutics, Inc.
0.0290
+1.75%